JP2006504723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006504723A5 JP2006504723A5 JP2004542620A JP2004542620A JP2006504723A5 JP 2006504723 A5 JP2006504723 A5 JP 2006504723A5 JP 2004542620 A JP2004542620 A JP 2004542620A JP 2004542620 A JP2004542620 A JP 2004542620A JP 2006504723 A5 JP2006504723 A5 JP 2006504723A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- gemcitabine
- acceptable salt
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 6
- 229960005277 gemcitabine Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 230000001093 anti-cancer Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 238000005755 formation reaction Methods 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 230000001772 anti-angiogenic Effects 0.000 claims 2
- 230000000259 anti-tumor Effects 0.000 claims 2
- 230000002137 anti-vascular Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (12)
- ヒトのような温血動物における抗血管形成及び/又は血管透過性減少作用の形成において使用するための医薬の製造におけるZD6474又はその薬学的に許容できる塩及びゲムシタビンの使用。
- ヒトのような温血動物における抗癌作用の形成において使用するための医薬の製造におけるZD6474又はその薬学的に許容できる塩及びゲムシタビンの使用。
- 抗癌作用が抗腫瘍作用を含む請求項2に記載の使用。
- 癌が膵臓癌である請求項2に記載の使用。
- 癌が肺癌である請求項2に記載の使用。
- 電離照射で処置されるヒトのような温血動物における抗血管形成及び/又は血管透過性減少作用の形成に使用するための医薬の製造におけるZD6474又はその薬学的に許容できる塩とゲムシタビンとの使用。
- 電離照射で処置されるヒトのような温血動物の抗癌作用の形成に使用するための医薬の製造におけるZD6474又はその薬学的に許容できる塩とゲムシタビンとの使用。
- 抗癌作用が抗腫瘍作用を含む請求項7に記載の使用。
- 癌が膵臓癌である請求項7に記載の使用。
- 癌が肺癌である請求項7に記載の使用。
- ZD6474又はその薬学的に許容できる塩と、ゲムシタビンとを、薬学的に許容できる賦形剤または担体と共に含む医薬組成物。
- ZD6474又はその薬学的に許容できる塩と、ゲムシタビンとを含むキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0223380.7A GB0223380D0 (en) | 2002-10-09 | 2002-10-09 | Combination therapy |
GB0223380.7 | 2002-10-09 | ||
PCT/GB2003/004334 WO2004032937A1 (en) | 2002-10-09 | 2003-10-06 | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010287659A Division JP2011088921A (ja) | 2002-10-09 | 2010-12-24 | 血管形成及び/又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体zd6474の使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006504723A JP2006504723A (ja) | 2006-02-09 |
JP2006504723A5 true JP2006504723A5 (ja) | 2006-11-24 |
JP5416328B2 JP5416328B2 (ja) | 2014-02-12 |
Family
ID=9945538
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004542620A Expired - Fee Related JP5416328B2 (ja) | 2002-10-09 | 2003-10-06 | 血管形成及び/又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体zd6474の使用 |
JP2010287659A Pending JP2011088921A (ja) | 2002-10-09 | 2010-12-24 | 血管形成及び/又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体zd6474の使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010287659A Pending JP2011088921A (ja) | 2002-10-09 | 2010-12-24 | 血管形成及び/又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体zd6474の使用 |
Country Status (23)
Country | Link |
---|---|
US (2) | US20060009418A1 (ja) |
EP (1) | EP1551409B1 (ja) |
JP (2) | JP5416328B2 (ja) |
KR (1) | KR101098061B1 (ja) |
CN (1) | CN100363004C (ja) |
AT (1) | ATE357236T1 (ja) |
AU (1) | AU2003269253B2 (ja) |
BR (1) | BR0315088A (ja) |
CA (1) | CA2501651C (ja) |
CY (1) | CY1106601T1 (ja) |
DE (1) | DE60312715T2 (ja) |
DK (1) | DK1551409T3 (ja) |
ES (1) | ES2282656T3 (ja) |
GB (1) | GB0223380D0 (ja) |
HK (1) | HK1078771A1 (ja) |
IL (1) | IL167633A (ja) |
MX (1) | MXPA05003595A (ja) |
NO (1) | NO330601B1 (ja) |
NZ (1) | NZ538999A (ja) |
PT (1) | PT1551409E (ja) |
SI (1) | SI1551409T1 (ja) |
WO (1) | WO2004032937A1 (ja) |
ZA (1) | ZA200502753B (ja) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
DE60134679D1 (de) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
KR101089462B1 (ko) | 2002-11-04 | 2011-12-07 | 아스트라제네카 아베 | Src 티로신 키나제 억제제로서의 퀴나졸린 유도체 |
NZ541297A (en) * | 2003-02-13 | 2008-03-28 | Astrazeneca Ab | Combination therapy of ZD6474 with 5-FU or/and CPT-11 |
EP1604665B1 (en) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
KR20120093411A (ko) * | 2003-07-10 | 2012-08-22 | 아스트라제네카 아베 | 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 zd6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도 |
EP1683785B1 (en) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
ES2322175T3 (es) | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | Composicion medicinal con estabilidad mejorada y gelificacion reducida. |
AU2005288737B2 (en) * | 2004-09-27 | 2008-08-14 | Astrazeneca Ab | Combination comprising ZD6474 and imatinib |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
MX2007016497A (es) * | 2005-07-06 | 2008-03-07 | Astrazeneca Ab | Terapia de combinacion para cancer con azd2171 y gemcitabina. |
WO2007014335A2 (en) * | 2005-07-27 | 2007-02-01 | The University Of Texas System | Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
PT1971338E (pt) * | 2005-12-22 | 2011-05-09 | Astrazeneca Ab | Combina??o de zd6474 e pemetrexed |
WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
CA2675736A1 (en) | 2007-01-19 | 2008-07-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
BR112017002827B1 (pt) | 2014-08-28 | 2023-04-18 | Eisai R&D Management Co., Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
MX2017010474A (es) | 2015-02-25 | 2017-11-28 | Eisai R&D Man Co Ltd | Metodo para suprimir el amargor de un derivado de quinoleina. |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
CN106727657A (zh) * | 2016-12-27 | 2017-05-31 | 郑州郑先医药科技有限公司 | 一种治疗糖尿病的西药组合物及应用 |
CN106619688A (zh) * | 2016-12-27 | 2017-05-10 | 郑州郑先医药科技有限公司 | 一种治疗糖尿病的药物组合物及应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL77133A (en) * | 1984-12-04 | 1991-01-31 | Lilly Co Eli | Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation |
US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
UA72946C2 (uk) * | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
US6953679B2 (en) * | 2000-09-19 | 2005-10-11 | Bristol-Myers Squibb Company | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
JP2006502132A (ja) * | 2002-08-09 | 2006-01-19 | アストラゼネカ アクチボラグ | 癌の治療における血管内皮細胞増殖因子受容体の阻害薬zd6474と放射線療法との併用 |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
NZ541297A (en) * | 2003-02-13 | 2008-03-28 | Astrazeneca Ab | Combination therapy of ZD6474 with 5-FU or/and CPT-11 |
KR20120093411A (ko) * | 2003-07-10 | 2012-08-22 | 아스트라제네카 아베 | 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 zd6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도 |
AU2005288737B2 (en) * | 2004-09-27 | 2008-08-14 | Astrazeneca Ab | Combination comprising ZD6474 and imatinib |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
MX2007016497A (es) * | 2005-07-06 | 2008-03-07 | Astrazeneca Ab | Terapia de combinacion para cancer con azd2171 y gemcitabina. |
PT1971338E (pt) * | 2005-12-22 | 2011-05-09 | Astrazeneca Ab | Combina??o de zd6474 e pemetrexed |
WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
US20100212978A1 (en) * | 2009-02-23 | 2010-08-26 | Wen-Hung Huang | Bicycle with two operation molds |
-
2002
- 2002-10-09 GB GBGB0223380.7A patent/GB0223380D0/en not_active Ceased
-
2003
- 2003-10-06 US US10/530,567 patent/US20060009418A1/en not_active Abandoned
- 2003-10-06 KR KR1020057005960A patent/KR101098061B1/ko active IP Right Grant
- 2003-10-06 NZ NZ538999A patent/NZ538999A/en not_active IP Right Cessation
- 2003-10-06 DE DE60312715T patent/DE60312715T2/de not_active Expired - Lifetime
- 2003-10-06 SI SI200330784T patent/SI1551409T1/sl unknown
- 2003-10-06 EP EP03751032A patent/EP1551409B1/en not_active Expired - Lifetime
- 2003-10-06 BR BR0315088-7A patent/BR0315088A/pt not_active IP Right Cessation
- 2003-10-06 AU AU2003269253A patent/AU2003269253B2/en not_active Ceased
- 2003-10-06 PT PT03751032T patent/PT1551409E/pt unknown
- 2003-10-06 WO PCT/GB2003/004334 patent/WO2004032937A1/en active IP Right Grant
- 2003-10-06 DK DK03751032T patent/DK1551409T3/da active
- 2003-10-06 ES ES03751032T patent/ES2282656T3/es not_active Expired - Lifetime
- 2003-10-06 MX MXPA05003595A patent/MXPA05003595A/es active IP Right Grant
- 2003-10-06 CA CA2501651A patent/CA2501651C/en not_active Expired - Fee Related
- 2003-10-06 CN CNB2003801011766A patent/CN100363004C/zh not_active Expired - Fee Related
- 2003-10-06 JP JP2004542620A patent/JP5416328B2/ja not_active Expired - Fee Related
- 2003-10-06 AT AT03751032T patent/ATE357236T1/de active
-
2005
- 2005-03-24 IL IL167633A patent/IL167633A/en active IP Right Grant
- 2005-03-29 NO NO20051575A patent/NO330601B1/no not_active IP Right Cessation
- 2005-11-24 HK HK05110642A patent/HK1078771A1/xx not_active IP Right Cessation
-
2006
- 2006-01-17 ZA ZA200502753A patent/ZA200502753B/en unknown
-
2007
- 2007-05-17 CY CY20071100670T patent/CY1106601T1/el unknown
-
2009
- 2009-08-14 US US12/541,647 patent/US20100120708A1/en not_active Abandoned
-
2010
- 2010-12-24 JP JP2010287659A patent/JP2011088921A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006504723A5 (ja) | ||
JP2005511597A5 (ja) | ||
JP2008514577A5 (ja) | ||
JP2006500346A5 (ja) | ||
CA2501651A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
WO2006035204A3 (en) | Combination comprising zd6474 and an imatinib | |
CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
JP2005530735A5 (ja) | ||
NO20064755L (no) | Kombinasjonsterapi | |
WO2004071397A3 (en) | Combination therapy of zd6474 with 5-fu or/and cpt-11 | |
WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine | |
BRPI0508983A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano | |
ATE429435T1 (de) | 7h-pyrrolopyrimidinderivate | |
CA2531620A1 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
JP2011500650A5 (ja) | ||
JP2007538066A5 (ja) | ||
ATE339209T1 (de) | Kombinationstherapie mit gemzitabin und zd6126 |